Laforin is a dual specificity protein phosphatase involved in Lafora disease (LD), a fatal form of progressive myoclonus epilepsy characterized by neurodegeneration and the presence of intracellular polyglucosan inclusions (Lafora bodies) in different tissues. In this work, we describe that mice lacking laforin (epm2a2/2) have enhanced insulin response leading to altered whole-body energy balance. This enhanced insulin response overactivates the Akt pathway which increases glucose uptake in the heart, resulting in increased glycogen levels and the formation of polyglucosan inclusions. In addition, enhanced insulin response resulted in increased liver lipid biosynthesis, resulting in hepatic steatosis. On the contrary, overexpression in rat hepatoma FTO2B cells of native laforin but not of a form lacking phosphatase activity (C266S) resulted in attenuation of insulin signaling. These results define laforin as a new regulator of insulin sensitivity, which provides novel insights into LD pathogenesis and identifies this phosphatase as a potential novel component of the insulin signaling cascade.
INTRODUCTION

Lafora progressive myoclonus epilepsy [Lafora disease (LD),
OMIM 254780] is a fatal autosomal recessive neurodegenerative disorder characterized by the presence of intracellular glycogen-like (polyglucosan) inclusions named Lafora bodies in different tissues (i.e. brain, heart, skeletal muscle; reviewed in 1,2). LD initially manifests during adolescence with generalized tonic -clonic seizures, myoclonus, absences, drop attacks and visual hallucinations. As the disease proceeds, a rapidly progressive dementia with apraxia, aphasia and visual loss ensues, leading patients to a vegetative state and death, usually within the first decade from onset of the first symptoms (1, 3) . Mutations causing LD have been identified in two genes, EPM2A (4,5) and EPM2B (NHLRC1) (6), although there is evidence for a third locus (7) . EPM2A encodes laforin, a dual specificity phosphatase with a functional carbohydrate binding domain at the N-terminus (8, 9) . EPM2B encodes malin, an E3-ubiquitin ligase with a RING finger domain at the N-terminus and six Ncl1, Ht2A, Lin41 containing motif domains in the C-terminal region which are involved in protein -protein interactions (6, 10, 11) . We and others have recently described that laforin interacts physically with malin and that laforin recruits specific substrates to be ubiquitinated by malin (10) (11) (12) . Some of these substrates are involved in the regulation of glycogen biosynthesis, such as the muscle isoform of glycogen synthase (13) , the glycogen debranching enzyme (14) and the R5/PTG glycogen targeting subunit of type 1 protein phosphatase (PP1) (12, 13, 15) . Recently, an alternative function of laforin on glycogen homeostasis has been described (16, 17) . Laforin would act as a phosphatase of complex carbohydrates and it has been proposed that this function might be necessary for the maintenance of normal cellular glycogen (18, 19) . Taken together, these results suggest a role for the laforin -malin complex in regulating glycogen biosynthesis, which is consistent with the presence of intracellular polyglucosan inclusions (Lafora bodies), as one of the histological determinants of LD. However, it is unclear at the moment whether the accumulation of Lafora bodies is the cause of the disease or whether they are secondary determinants of a primarily established metabolic alteration.
As mentioned above, laforin is a protein phosphatase with a typical dual specificity phosphatase domain at the C-terminus. Accordingly, recombinant laforin is able to dephosphorylate in vitro artificial substrates such as p-nitrophenylphosphate (20) (21) (22) . In addition to the capacity of laforin to dephosphorylate glycogen (see above), it has been suggested that laforin dephosphorylates proteinaceous substrates such as glycogen synthase kinase 3b (GSK3b) (23, 24) , although this is a controversial issue (16, 17) .
Although LD is considered a neurological disorder, in some patients, the first manifestations of the disease are extraneurological symptoms, such as hepatic disease (25, 26) or cardiac arrhythmia (27) . To fully understand the metabolic alterations underlying LD, we have used a mouse model of LD lacking laforin (epm2a 2/2 mice; 28). Our results indicate that epm2a 2/2 mice have enhanced insulin response leading to altered whole-body energy balance. These results suggest an unexpected negative role of laforin in the regulation of insulin sensitivity, which provides novel insights into LD pathogenesis and identifies this phosphatase as a potential novel component of the insulin signaling cascade.
RESULTS
Epm2a
2/2 mice have increased lipid biosynthesis in the liver
To fully understand the metabolic alterations underlying LD, we have used a mouse model of LD lacking laforin (epm2a 2/2 mice; 28). Control and epm2a 2/2 mice were fed ad libitum with a regular chow diet. At 9 weeks of age, we observed that male epm2a 2/2 mice presented a statistically significant increase in body weight that was maintained with time ( Fig. 1A) , although the animals showed a similar length from head to the base of the tail as control mice, at any age (data not shown). The increase in body weight was concomitant with an increased food intake throughout the study [ Fig. 1B ; values at 3 months (12 weeks) of age]. Similar increase in body weight and food intake was observed in female epm2a
2/2 mice (data not shown). Animals were sacrificed at 3 months of age (12 weeks) to perform a metabolic analysis. As it is shown, the epm2a 2/2 mice presented higher levels of triglycerides ( Fig. 1C) and cholesterol ( Fig. 1D ) in the plasma, both in the fed state and after 12 h of starvation. The levels of non-sterified fatty acids (NEFA) and ketone bodies (3-hydroxybutyrate) were also higher in the plasma of epm2a 2/2 mice (Fig. 1E ). These higher plasma lipid levels correlated with a higher adiposity of the epm2a 2/2 mice, as suggested by the magnetic resonance analysis of body mass composition (Fig. 1F) .
Since liver is a key tissue involved in lipid biosynthesis, we analyzed the levels of triglycerides and cholesterol in this tissue and observed a clear increase in the content of both lipids in the liver of epm2a 2/2 mice ( Fig. 2A) . Hematoxylin -eosin and Nile red staining of liver samples also showed an accumulation of lipid droplets in the liver of epm2a 2/2 mice in comparison with control animals (Fig. 2B ). This increase in lipid content was concomitant with higher contents of the enzymes involved in their biosynthesis, such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC) (Fig. 2C ). In the liver of the epm2a 2/2 mice, we also detected higher content of the lipogenic transcription factor sterol regulatory element-binding protein 1c (SREBP1c), both in its precursor (SREBP1c-p) and active mature (SREBP1c-m) forms (Fig. 2C ). To confirm these results, we analyzed by quantitative real time polymerase chain reaction (qRT-PCR) the expression of different key metabolic genes. Among them, we observed a clear increase in the expression of lipogenic genes, such as SREBP1, FAS and ACC2. The expression of low density lipoprotein receptor, another SREBP1c target gene, was also increased (Fig. 2D) . However, the expression of other lipid-related genes was unaffected as in the case of those encoding fatty acid transporter (CD36), liver X receptor, ATP-binding cassette subfamily A member 1 (a cholesterol efflux regulatory protein), apolipoprotein E, SREBP2, HMGCoA-reductase and squalene synthase (Supplementary Material, Fig. S1 ). Finally, we detected lower expression levels of phosphoenol pyruvate carboxykinase (PEPCK), a key gluconeogenic gene (Fig. 2D ), but no effect on the levels of glucose-6-phosphatase (G6Pase) and peroxisome proliferator-activated receptor g co-activator 1-a, other genes involved in the gluconeogenic pathway (Supplementary Material, Fig. S1 ). All these results were consistent with a clear lipogenic profile of the liver of epm2a 2/2 mice.
Epm2a
2/2 mice have enhanced glucose disposal with increased energy expenditure but similar spontaneous locomotor activity
As described in Figure 3A , fed epm2a 2/2 mice presented lower basal levels of blood glucose, a difference that was much larger when the mice were fasted for 12 h. However, the plasma insulin levels were similar in control and epm2a 2/2 animals whatever the nutritional conditions (Fig. 3B) . The hypoglycemia present in epm2a 2/2 mice could be due to an impaired liver glucose production, to an enhanced glucose disposal or to both. To analyze the first possibility, we measured the levels of liver glycogen under basal conditions and after a starvation of 12 and 24 h. As it is shown in Figure 3C , the liver of both, fed control and epm2a 2/2 animals, contained similar amounts of glycogen that were reduced to similar levels upon starvation. Therefore, the liver of both groups of animals performed a regular glycogen breakdown upon starvation conditions. These results are consistent with the absence of polyglucosan inclusions (Lafora bodies) in the liver of epm2a 2/2 mice (28). Hypoglycemia was neither due to increased accumulation of glucose in the form of glycogen in skeletal muscle since, at 3 months of age, we did not detect any significant difference in the levels of glycogen in skeletal muscle between control and epm2a 2/2 mice (Fig. 3D ), in agreement with previous results (17) . Therefore, hypoglycemia could be secondary to a reduced gluconeogenic capacity, since PEPCK expression was reduced (Fig. 2D ), or to an enhanced glucose disposal.
We then performed a glucose tolerance test (GTT) in animals after a 12 h fast. As shown in Figure 4A , the intraperitoneal injection of a bolus of glucose induced in the control mice a clear increase in plasma glucose levels, which dropped 30 min after the injection. Surprisingly, in epm2a 2/2 mice, plasma glucose levels increased only slightly, resulting in an almost blunted response to the GTT. This decreased glucose response was not due to increased levels of insulin. Insulin concentrations at time 0 and 30 min after the glucose injection even showed a trend to be lower in the epm2a 2/2 mice, although the differences were not statistically significant (Fig. 4B ). Similar GTT performance was observed in female epm2a 2/2 mice (Supplementary Material, Fig. S2 ). In order to explain the enhanced glucose disposal, we measured energy expenditure, oxygen consumption and spontaneous locomotor activity. As it is observed in Figure 4C and D, epm2a 2/2 mice have a significant increase in diurnal energy expenditure and oxygen consumption. During a 3-day period of analysis, food intake and water intake were also significantly higher in epm2a 2/2 mice compared with controls ( Supplementary Material, Fig. S3) . Notably, the difference in energy expenditure between the epm2a 2/2 and control mice were not explained by an increase in total spontaneous locomotor activity, which was similar between epm2a 2/2 and control mice (Fig. 4F) , although the diurnal and nocturnal distribution of the ambulation was significantly different (Fig. 4F) . Respiratory exchange rate (respiratory quotient, RQ), which is an indicator of which fuel (carbohydrate or fat) is being metabolized, indicates that during the nocturnal period epm2a 2/2 and control mice use a similar carbohydrate substrate (Fig. 4E) , whereas during the diurnal phase epm2a 2/2 mice show a significant increase in RQ (Fig. 4E ). These results correlate with a higher energy expenditure ( 
2/2 mice have increased insulin response
In order to check whether the enhanced glucose disposal was related to an enhanced insulin response, we performed an insulin tolerance test (ITT). We injected intraperitoneally a low insulin dose (0.25 UI/kg) to avoid severe hypoglycemia and we measured the levels of plasma glucose after the injection. In the control mice, insulin injection produced initially a drop of the levels of glucose; then the levels of glucose increased to almost reach basal levels 2 h after the injection (Fig. 5A ). However, in the epm2a 2/2 mice, insulin injection resulted in a marked drop in the glucose levels that did not reach basal levels even 2 h after the injection (Fig. 5A) . We reduced the levels of insulin to 0.1 UI/kg and after 10 min of treatment we observed in the control mice that this amount of insulin was not able to produce changes in the levels of glucose (data not shown). On the contrary, in the epm2a 2/2 mice, glucose levels decreased by 25%, indicating an enhanced insulin response. Since it has been described that skeletal muscle is responsible for around 80% of insulin-stimulated glucose uptake (29) , insulin-treated animals were sacrificed and insulin signaling analyzed in skeletal muscle (soleus). As shown in Figure 5B , epm2a 2/2 mice presented higher levels of phosphorylated Akt (both at the catalytic Thr308 and the regulatory Ser473 residues) in comparison with control animals. The increased levels of activated Akt correlated with increased levels of phosphorylated Akt substrates, such as pSer9-GSK3b. These results indicated that epm2a 2/2 mice were more sensitive to insulin, since they were able to trigger insulin signaling at very low insulin concentrations.
We also measured insulin-induced glucose transport in different tissues by the injection of a bolus of the non-metabolizable analogue 2-deoxy-D- [1- 14 C]glucose (2DG). In epm2a
mice, there was a trend for increased glucose utilization in diaphragm, tibialis and soleus skeletal muscles, which reached statistical significance in the heart (Fig. 6A) . To confirm the enhanced glucose disposal in peripheral tissues, mice were starved for 12 h and then subjected to positron emission tomography (PET)/axial computerized tomography (TAC) analysis. [ 18 F]-fluorodeoxyglucose (FDG) was injected and the appearance of the marker in different tissues was recorded. Normalizing the levels of FDG in the bladder of all the animals (the marker is eliminated by urine), we found that epm2a 2/2 animals showed a much larger accumulation of the FDG marker in the heart (Fig. 6B ).
In conclusion, our results indicate that epm2a 2/2 mice have an enhanced glucose disposal probably as a result of increased insulin response.
The insulin signaling response is enhanced in the heart and liver of epm2a 2/2 mice
Since the heart of epm2a 2/2 mice was the tissue that showed the most enhanced glucose accumulation, we analyzed the insulin signaling pathway in this tissue. Mice were treated with a high dose of insulin (1 UI/kg) and 10 min after the injection they were sacrificed and analyzed for the insulin signaling pathway. We observed higher levels of phosphorylated Akt (both at the catalytic Thr308 and the regulatory Ser473 residues) in epm2a 2/2 mice in comparison with control animals (Fig. 7A) . The increased levels of activated Akt correlated with increased levels of phosphorylated Akt substrates, such as pSer9-GSK3b, and downstream effectors such as pThr389-p70S6kinase (Fig. 7A) . These results could suggest that the increased glucose uptake observed in this tissue (see above) could be due to an enhanced insulin-mediated increase in glucose transport. In this sense, we observed higher contents of GLUT4 in epm2a 2/2 cardiomyocytes, especially in samples from insulin-treated animals (Fig. 7B) . The increase in glucose uptake induced the accumulation of glycogen in epm2a 2/2 cardiomyocytes (Fig. 7C ) and the appearance of periodic acid-Schiff (PAS) -positive inclusions, characteristic of polyglucosan depositions (Lafora bodies) (Fig. 7D) . These metabolic changes could be the cause of the altered cardiac functions described in some LD patients (27) .
We then extended our analysis of the insulin signaling pathway to the liver. Upon insulin treatment, we also observed higher levels of phosphorylated Akt (both at the catalytic Thr308 and the regulatory Ser473 residues) in epm2a 2/2 mice in comparison with control animals that correlated with increased levels of phosphorylated Akt substrates, such as pSer9-GSK3b and pSer256-FOXO1, and downstream effectors, such as pThr389-p70S6kinase (Fig. 8A) .
In order to confirm the negative role of laforin on insulin signaling, we overexpressed laforin in rat hepatoma FTO2B cells. These cells were infected with adenovirus expressing Figure 3 . Glycemia, insulinemia and liver glycogen content in epm2a 2/2 mice. Blood glucose (A) and plasma insulin (B) levels were measured in 3-month-old control (black bar) and epm2a 2/2 (white bar) mice, fed or fasted for 12 or 24 h. Glycogen levels in liver (C) and skeletal muscle (D) were also measured in these animals as described in Materials and Methods. Values in all the cases are means + SEM from five to six mice per group. Statistical significance:
* P , 0.05 and * * P , 0.01.
either GFP (as control), wild-type laforin or an inactive phosphatase form of laforin which has the catalytic Cys residue changed by a Ser (C266S). As shown in Figure 8B , overexpression of wild-type laforin but not laforin C266S resulted in a decreased insulin-induced phosphorylation of Akt (pSer473). The negative effect of laforin on insulin signaling was also observed in infected mouse embrionic fibroblast (MEF) cells from epm2a 2/2 mice: overexpression of wild-type laforin but not laforin C266S decreased the activation of Akt in the presence of insulin (Supplementary Material, Fig. S4 ). Therefore, overexpression of native laforin diminishes insulin signaling, whereas depletion of laforin (epm2a 2/2 mice) enhances it.
Finally, we tested insulin response in white adipose tissue. However, in this case, we did not observe differences in the phosphorylation status of Akt between control and epm2a 2/2 mice (Supplementary Material, Fig. S5 ).
DISCUSSION
All the experiments described in this work point to an enhanced glucose disposal in epm2a 2/2 mice. These animals clear a glucose load much more rapidly than control mice and their glucose utilization rate is higher despite a lower glycemia. The enhanced glucose disposal correlates with an increased energy expenditure, although total spontaneous locomotor activity was similar between epm2a 2/2 and control mice. Since the higher glucose clearance is not due to increased glucose secretion in the urine (data not shown), this enhanced glucose disposal could be probably due to an increased glucose utilization in insulin sensitive tissues. In this sense, we have found in the liver of epm2a 2/2 mice an enhanced lipogenic capacity, secondary to an increased expression and maturation of the SREBP-1c transcription factor, a process which is highly dependent upon insulin. In skeletal muscles, we found a trend for an enhanced glucose utilization in response to insulin and a clearcut increase for heart glucose utilization, linked to an enhanced expression of GLUT4, a process again highly dependent from insulin. This enhanced uptake of glucose resulted in the heart in an increase in the levels of glycogen and the formation of polyglucosan inclusions (Lafora bodies). In summary, many insulin-dependent processes are over-activated in epm2a 2/2 mice, such as an increased hepatic lipogenic capacity and triglyceride synthesis and the increase in muscle glucose uptake in the heart. It is likely that, according to the glucose-fatty acid cycle (Randle cycle) (30), the huge increase in glucose uptake in the heart of epm2a 2/2 mice would displace its regular preferred substrate for oxidation from fatty acids to glucose, leading to the accumulation of NEFA in the serum. Similar increased levels of NEFA have been described in other mice models with improved glucose tolerance and higher insulin sensitivity (31, 32) .
Although insulin secretion was not directly studied here, insulin levels seem appropriate for the prevailing glycemia after a 12 h fast. It is thus likely that an enhanced insulin response is a key factor in order to explain the phenotype of epm2a 2/2 mice. We also present strong evidence to conclude that insulin sensitivity is indeed increased in epm2a 2/2 mice: (i) the drop in plasma glucose after an ITT is much more marked in epm2a 2/2 mice than in controls; (ii) skeletal muscle, liver and heart of the epm2a 2/2 mice responded more strongly to insulin, as detected by an activated Akt pathway. Correspondingly, the phosphorylation of Akt-related substrates, such as pGSK3b and pFOXO1 and downstream effectors (p70S6kinase), is enhanced. It has been proposed that laforin dephosphorylates pGSK3b (23, 24) . Our results show higher levels of pGSK3b in epm2a 2/2 animals, but this could be a consequence of the over-activated PI3Kinase-Akt pathway. An increased hepatic insulin sensitivity may sound paradoxical in the presence of increased lipid deposition. Although it is clear that hepatic steatosis induced by carbohydrate or lipid large overfeeding is concomitant with insulin resistance (i.e. ob/ob mice, fa/fa rats, high fat feeding), this correlation does not occur in other models. For instance, in hepatocytes in which the adipose triacylglycerol lipase is depleted and which accumulate large quantities of triglycerides, insulin sensitivity is not affected (33) . Similar results were obtained in mice depleted for Gene Identification-58 (CGI-58) (34) . These results may reflect that depending upon the model, different fatty acid species with various degrees of lipotoxicity may accumulate in the liver, affecting insulin sensitivity in different degrees.
In agreement with a negative role of laforin on insulin sensitivity, overexpression of native laforin diminishes insulin signaling. Experiments in hepatoma FTO2B cells and MEF cells from epm2a 2/2 mice overexpressing wild-type laforin indicated that this phosphatase attenuated insulin signaling. The phosphatase activity of laforin seems to be crucial in this modulation since an inactive form of laforin (C266S) is not able to attenuate insulin signaling. Studies are on course to determine the molecular mechanism of action of laforin on the insulin signaling pathway. Preliminary experiments in the liver of epm2a 2/2 and control mice indicate no differences in the amount or in the insulin-dependent phosphorylation of insulin receptor (IR) and in the amount of IRS1 and IRS2 (Supplementary Material, Fig. S6A ). The amount of phosphatidylinositol-3,4,5 triphosphate (PIP3) was also similar between both sets of animals in either basal or insulin-treated conditions (Supplementary Material, Fig. S6B ). In addition, hepatoma FTO2B cells overexpressing laforin presented similar levels of IR, IRS1, IRS2, p85-PI3kinase and PDK1 than non-overexpressing cells (Supplementary Material, Fig. S6C and D) , and p85-PI3kinase was co-immunoprecipitated with anti-IRS1 or anti-IRS2 antibodies at similar extent in laforin-overexpressing and nonoverexpressing cells (Supplementary Material, Fig. S6D) . Moreover, the levels of JNK1 and the insulin-induced phosphorylation of this kinase were also similar in cells overexpressing or not laforin (Supplementary Material, Fig. S6C ), and the levels of pSer307-IRS1 (a substrate of JNK1) followed the same trend in either laforin overexpressing and nonoverexpressing cells (Supplementary Material, Fig. S6C ). All these results indicate that laforin does not affect the initial steps of insulin signaling. Since we have recently reported that laforin acts upstream of the TSC1/TSC2 complex (35), our results suggest that laforin should be affecting steps beyond PI3kinase and upstream of mTOR.
We have also observed that food intake of epm2a 2/2 mice is higher than control mice. Although it is likely that the continuous hypoglycemia can be a potent stimulus for an enhanced food intake (36), we cannot rule out a direct effect of the absence of laforin in hypothalamic nuclei responsible for the control of food intake. We are currently testing this hypothesis.
In summary, our studies reveal an unexpected negative role of laforin in the regulation of insulin sensitivity, which provides novel insights into LD pathogenesis. These results could explain why, in some cases, LD is presented with an altered hepatic metabolism (25, 26) or with an altered cardiac function (27) .
MATERIALS AND METHODS
Animals
Laforin-deficient epm2a
2/2 mice were kindly provided by Dr Antonio V. Delgado-Escueta (28) . These animals are reported to have a C57BL/6J genetic background and have been used as a model of LD in other laboratories (17, 19, 37) . Male C57BL/6J wild-type (Jackson Laboratories, Maine, USA) and epm2a 2/2 mice were maintained at the Centro de Investigaciones Biologicas (CIB-CSIC, Madrid) on a light/dark 12:12 h cycle under constant temperature (238C) with free access to water and regular chow diet (65% carbohydrate, 11% fat, 24% protein). Female epm2a 2/2 and control mice were also used when indicated. Body weight and blood glucose levels were measured weekly between 9 a.m. and 10 a.m. Mice were sacrificed by cervical dislocation, blood samples, skeletal muscles, liver and heart were dissected and tissue extracts were obtained as described below. All animal care and procedures used in this study were in accordance with the Declaration of Helsinki Figure 7 . Insulin signaling is improved in the heart of epm2a 2/2 mice. (A) Control and epm2a 2/2 mice were fasted for 12 h and then injected with insulin (1 UI/ kg body weight) or with vehicle. After 10 min, animals were sacrificed and heart extracts analyzed by western blotting using the indicated antibodies. A representative western blot is presented in each case. Fold intensity of the phosphorylated bands was related to the intensity of the corresponding total protein. Values in all the cases are means + SEM from three to five mice per group. Statistical significance:
* P , 0.05 and * * P , 0.01. (B) Heart samples were analyzed by immunofluorescence using anti-GLUT4 antibodies. A size bar is indicated. (C) Glycogen levels were measured in saline-treated heart samples as described in Materials and Methods. Values are means + SEM from five to six mice per group. Statistical significance:
* P , 0.05. (D) Saline-treated heart samples were analyzed by PAS staining as described in Materials and Methods; magnification fold is presented.
principles and the guidelines from the Institutional Animal Care and Use Committee, and approved by the Centro de Investigaciones Biologicas (CIB-CSIC) ethical review board.
Cell culture and treatments
Rat hepatoma FTO2B cell line was grown in Dulbecco's modified eagle medium (DMEM) (Lonza, Barcelona, Spain) supplemented with 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine, 10% inactivated fetal bovine serum (FBS, GIBCO, Madrid, Spain). 10 6 cells were plated onto 60 mm diameter culture dishes the day before adenoviral infection. Infection with the corresponding adenovirus was carried out in 1 ml of complete DMEM containing 0.5% FBS. Adenovirus used in this work were Ad-GFP (10 11 pfu/ ml), Ad-laforin (2 × 10 12 pfu/ml) and Ad-laforin C266S Figure 8 . Laforin affects insulin signaling in liver. (A) Control and epm2a 2/2 mice were fasted for 12 h and then injected with insulin (1 U/kg body weight) or with vehicle. After 10 min, animals were sacrificed and liver extracts analyzed by western blotting using the indicated antibodies. A representative western blot is presented in each case. Fold intensity of the phosphorylated bands was related to the intensity of the corresponding total protein. Values in all the cases are means + SEM from three to five mice per group. Statistical significance:
* P , 0.05. (B) Overexpression of laforin in hepatoma FTO2B cells attenuates insulin signaling. Hepatoma FTO2B cells were infected with adenovirus expressing GFP (Ad-GFP), laforin (Ad-Laf) or a laforin form which lacks phosphatase activity (Ad-C266S). Infected cells were treated or not with 100 nM insulin for the indicated times and then cell extracts were obtained. These extracts were analyzed by western blotting using the indicated antibodies. A representative western blot is presented in each case. Intensity of the phosphorylated Akt bands was related to the intensity of the corresponding total Akt protein. The ratio was adjusted to 1 in the case of the response to insulin at 15 min in cells transfected with Ad-GFP and the other values were referred to this ratio. Values in all the cases are means + SEM from at least three independent assays. Statistical significance:
* P , 0.05 and * * P , 0.01 between Ad-Laf and Ad-GFP or ## P , 0.01 between Ad-Laf and Ad-C266S.
(2 × 10 12 pfu/ml) (12) . Two hours after infection, adenoviruscontaining medium was replaced with fresh complete DMEM containing 0.5% FBS. Twenty-four hours after infection, cells were treated or not with 100 nM insulin for the indicated times. Then, cells were washed with PBS and frozen in liquid N 2 until further analysis. Cells were lysed by repeated passage through a 25-gauge needle on ice in lysis buffer [50 mM Tris-HCl pH 7.5; 10 mM NaCl, 50 mM ethylendiamine tetracetic acid (EDTA); 15% glycerol, 1% nonidet P-40 (NP-40), complete protease inhibitor cocktail (Roche Diagnostics, Barcelona, Spain), 1 mM phenylmethyl sulfonyl fluoride (PMSF), 50 mM NaF and 5 mM Na 2 P 2 O 7 ]. Twenty-five micrograms of total protein from the soluble fraction of cell lysates were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting as described below. Similar experiments were performed with MEF cells from epm2a 2/2 mice. They were grown in complete DMEM supplemented with 15% FBS and treated as described for hepatoma FTO2B cells.
Analytical procedures
Fasting blood samples were taken from mice 12 h after withdrawal of food (9 a.m. in the morning). Samples from fed animals were also taken at the same time. Blood glucose concentrations were measured from blood sampled in the tail vein using a glucometer (Arkray, Kyoto, Japan). Different enzymatic assay kits were used for plasma chemistry analyses, including cholesterol and triglycerides (Wako Chemicals, Neuss, Germany), NEFA and b-3-hydroxybutyrate (Randox, Barcelona, Spain). For the determination of liver cholesterol and triglyceride content, 50-100 mg tissue pieces were homogenized at room temperature in an extraction buffer (0.2 M sodium acetate pH 4.5); then, cholesterol and triglycerides levels were measured as described above. Insulin levels were determined in duplicate in each sample, using a mouse insulin (Mercodia, Uppsala, Sweden) enzyme-linked immunosorbent assay kit, according to the manufacture's protocol.
Glucose tolerance test (GTT)
After 12 h of fasting, mice received an intraperitoneal bolus of D-glucose (2 g/kg body) and blood glucose concentration was measured in samples taken at 0, 5, 15, 30, 60 and 120 min after glucose injection.
Insulin tolerance test (ITT)
Mice fasted for 3 h received an intraperitoneal injection of 0.25 UI/kg of recombinant human insulin (Humulin, Lilly, Madrid, Spain). Blood glucose levels were determined at 0, 15, 30, 60, 90 and 120 min after injection. In each group of animals, values were referred to the levels of glucose found at time 0 of the assay (100%).
Glycogen quantification
Glycogen determination was carried out homogenizing 100 mg of mice tissue into ice-cold 30% potassium hydroxide and the extract was then heated at 1008C for 15 min. Glycogen was then measured as described previously (38) . The amount of glycogen was expressed as the amount of released glucose per milligram of total protein.
Indirect calorimetry measurements and metabolic phenotyping
Metabolic phenotyping was carried out using the Functional & Physiological Exploration Platform (FPE) of the unit Functional & Adaptive Biology (BFA) University Paris Diderot-Paris 7, CNRS EAC 4413. Mice were analyzed for whole energy expenditure (Kcal/kg lean/h), oxygen consumption/carbon dioxide production (VO 2 , VCO 2 ; ml/kg lean/h), respiratory exchange rate (RQ ¼ VCO 2 /VO 2 ), food and water intake (g) as well as locomotor activity (counts/h) using 12 calorimetric cages (Labmaster, TSE Systems GmbH, Bad Homburg, Germany). Ratio of gases was determined through an indirect open circuit calorimeter (39, 40) . This system monitors O 2 and CO 2 concentration by volume at the inlet ports of a tide cage through which a flow of air (0.4 l/min) is being ventilated and compared regularly to a reference empty cage. Whole energy expenditure is calculated according to the Weir equation respiratory gas exchange measurements (41) . Sensors were previously calibrated with O 2 and CO 2 mixture of known concentrations (Air Liquide, Paris, France). The instrument combined a set of highly sensitive feeding and drinking sensors for automated online measurement, and each cage is embedded in a frame with an infrared light beambased activity monitoring system, allowing measurement of total locomotion. The sensors for gases and detection of movement operate efficiently in both light and dark phases, allowing continuous recording.
Mice were individually housed in the cage, in a calm surroundings with lights on from 07:00 to 19:00 h and an ambient temperature of 22 + 18C. All animals were acclimated for 48 h and the baseline parameters were established within the next 72 h. Mice had free access to chow diet and water ad libitum. Data were collected every 40 min during the experimental times. Data analysis were performed on excel XP using extracted raw value of VO 2 consumed, VCO 2 production (expressed in ml/h), energy expenditure (Kcal/h). Subsequently, each value was expressed either by total body weight or whole lean tissue mass extracted from the EchoMRI analysis (see below). Representative 24 h measurements were the mean of the three consecutive experimental days.
Body mass composition
Body mass composition (lean tissue mass, fat mass, free water and total water content) was analyzed using an Echo Medical systems' EchoMRI 900 (Whole Body Magnetic Resonance Analyzer, EchoMRI, Houston, TX, USA) according to the manufacturer's instructions (42) . Briefly, conscious mice were weighed before they were put in a mouse holder and inserted in the MR analyzer. Readings of body composition were given within 1 min.
Insulin-induced glucose uptake
Mice subjected to an insulin infusion kept constant at 0.2 UI/kg/h (3.33 mU/kg/min), received a bolus injection of 2-deoxy-D-[1-Cortaboeuf, France). In vivo glucose uptake (mg/g of tissue/min) for muscle (tibialis anterior, soleus, gastrocnemius, diaphragm, heart), white adipose tissue (subcutaneous, visceral), brain, liver, kidney and pancreas was calculated based on the accumulation of 2DG6P in the respective tissue and the disappearance rate of 2DG from plasma as described (43) . Immunoreactive insulin was determined with an enzyme-linked immunosorbent assay kit (Crystal Chem Inc, Downers Grove, IL, USA).
Positron emission tomography (PET)
Mice starved for 12 h were anesthetized with isoflurane [1.5 -2% in 100% oxygen, IsoFlo (Abbott Laboratories, Madrid, Spain)] and injected intravenously with 
Obtaining cell extracts and immunodetection
Tissue lysates from mice were prepared by homogenizing samples with a tissue homogenizer in ice-cold lysis buffer containing 10 mM Tris -HCl pH 7.5, 0.15 M NaCl, 15 mM EDTA pH 8.0, 0.6 M sucrose, 0.5% NP-40, 50 mM NaF, 5 mM Na 2 P 2 O 7 , 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml benzamidine, 1 mg/ml DTT, 1 mM PMSF and protease inhibitor cocktail (Roche Diagnostics). Protein content was determined using the Bradford method (Bio-Rad, Madrid, Spain). Thirty micrograms of total protein from the soluble fraction of lysates were analyzed by SDS -PAGE and western blotting using appropriate antibodies. Blocking was performed in 5% non-fat milk for 1 h at room temperature. Blots were probed with indicated antibodies at 1:1000 dilution in TBS-T (50 mM Tris -HCl, 154 mM NaCl, pH 7.5 plus 0.1% Tween 20) plus 5% non-fat milk. Antibodies used in this study were from the following sources: ACC, Akt, P-Akt(Ser473), P-Akt(Thr308), FAS, FOXO1, P-FOXO1(Ser256), GSK3b, P-GSK3b(Ser9), P-IR, p(Thr183/Tyr185)-JUNK1, JUNK1, pPDK1, p70S6kinase and P-p70S6kinase(Thr388), from Cell Signaling (Danvers, MA, USA); IRS1, IRS2, pSer307 IRS1 and p85-PI3K from Millipore (Madrid, Spain); tubulin and IR, from Santa Cruz Biotech (Santa Cruz, CA, USA); SREBP1c, from BD Biosciences; Actin, from Sigma (Madrid, Spain); laforin (46) .
Histological analysis
Liver tissues were fixed in 10% neutral-buffered formalin, embedded in paraffin and cut into 7 mm sections. Sections were stained with hematoxylin -eosin (Sigma) and analyzed at ×63 magnification using a Leica DMRXA2 microscope and the Leica FW4000 software (Barcelona, Spain). For Nile red staining (Sigma), after formalin fixation liver tissues were incubated overnight with sucrose 30%, then frozen in isopentane and kept at 2808C. Sections of 7 mm were obtained and analyzed at ×63 magnification as above. Heart sections were fixed as described above. Glycogen was stained with the PAS system (Sigma) and analyzed at ×100 magnification. Heart sections were also incubated with a rabbit polyclonal anti-GLUT4 antibody (1:500 dilution; Millipore) in PBS-Triton 0.5% with 10% FBS overnight at 4 8C. After the incubation, slides were rinsed with PBS-Triton 0.5% three times and then incubated with fluoresceinconjugated rabbit anti-goat IgG (1:1000 dilution; Molecular Probes, Madrid, Spain) for 60 min at 37 8C, followed by another three rinses with PBS-Triton 0.5%. Sections were also stained with rhodamine phalloidin and TOPRO-3 for nuclei visualization. The slides were mounted and images were acquired for 2 mm slices with a Leica TCS/SP2 confocal microscope (Barcelona, Spain) using a ×63 oil-immersion objective. Images were treated with the ImageJ 1.43c software (Wayne Rasband, Washington, D.C., USA).
Quantitative real-time PCR
Dissected tissues from mice were frozen in liquid nitrogen and stored at -808C. Thawed tissue was homogenized in 2 ml TRIPURE reagent (Roche Diagnostics) and total RNA was isolated according to the manufacturer's instructions. The integrity of total RNA was verified by electrophoresis through denaturing agarose gels. First-strand cDNA was synthesized from 1 mg of total RNA using random hexamer and expand reverse transcriptase (Roche Diagnostics). cDNA was used as a template for real-time PCR. Taqman probes for each gene were designed using Universal probe library Service (Roche Molecular Biochemicals, Barcelona, Spain) to meet all TaqMan design guidelines. Probes were synthesized with a reporter dye 6-carboxyfluorescein covalently linked at the 5 ′ end and a quencher dye 6-carboxy-tetramethyl-rhodamine was linked to the 3 ′ end of the probe (see Supplementary Material, Table S1 for primer sequences). Each PCR was carried out in a final volume of 25 ml of PCR Master Mix (Applied Biosystems, Madrid, Spain), containing 200 nM of each primer and 40 nM of specific fluorescent probe. The cycle conditions were 20 s at 958C for initial denaturing, followed by 35 cycles of 958C for 3 s and 608C for 30 s in the 7500 Fast Real-time PCR system (Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal standard. Each reaction was done in duplicate for each sample. The relative amount of each mRNA was calculated using the second derivative comparative Ct method.
Statistical analyses
Values are given as means + SEM of at least three independent experiments. Differences between groups were analyzed by two-tailed student's t-tests. The significance has been considered at * P , 0.05, * * P , 0.01 and * * * P , 0.001, as indicated in each case.
